Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Citi
Argus Health
Harvard Business School
Covington
Julphar
Chubb
Accenture

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 070916

« Back to Dashboard

NDA 070916 describes NALBUPHINE HYDROCHLORIDE, which is a drug marketed by Abbott, Abbvie, Barr, Hospira, and Igi Labs Inc, and is included in thirteen NDAs. It is available from four suppliers. Additional details are available on the NALBUPHINE HYDROCHLORIDE profile page.

The generic ingredient in NALBUPHINE HYDROCHLORIDE is nalbuphine hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nalbuphine hydrochloride profile page.
Summary for 070916
Tradename:NALBUPHINE HYDROCHLORIDE
Applicant:Hospira
Ingredient:nalbuphine hydrochloride
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 070916
Medical Subject Heading (MeSH) Categories for 070916
Suppliers and Packaging for NDA: 070916
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NALBUPHINE HYDROCHLORIDE nalbuphine hydrochloride INJECTABLE;INJECTION 070916 ANDA Hospira, Inc. 0409-1465 N 0409-1465-01
NALBUPHINE HYDROCHLORIDE nalbuphine hydrochloride INJECTABLE;INJECTION 070916 ANDA McKesson Packaging Services Business Unit of McKesson Corporation 63739-466 E 63739-466-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength20MG/ML
Approval Date:Feb 3, 1989TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Medtronic
Fish and Richardson
Argus Health
Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.